NDAQ:PRLD - Post Discussion
Post by
whytestocks on Apr 09, 2024 4:45pm
Prelude Highlights Continued Strength of Discovery Engine at
News; $PRLD Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingHighly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematolo...
PRLD - Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Be the first to comment on this post